Bio-Techne (TECH) Common Equity (2009 - 2026)

Bio-Techne has reported Common Equity for 18 years, with the latest figure at $2.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 3.33% year-over-year to $2.1 billion; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (up 3.33% YoY), and the FY2025 full-year result was $1.9 billion, down 7.25% from the prior year.
• Common Equity for Q1 2026 stood at $2.1 billion, up from $2.0 billion in the prior quarter.
• The five-year high for Common Equity was $2.1 billion in Q3 2024, with the low at $1.7 billion in Q2 2022.
• Average Common Equity over 5 years is $1.9 billion, with a median of $2.0 billion recorded in 2023.
• Year-over-year, Common Equity increased 15.61% in 2023 and decreased 8.08% in 2025.
• Tracing TECH's Common Equity over 5 years: stood at $1.8 billion in 2022, then increased by 7.47% to $2.0 billion in 2023, then advanced by 5.85% to $2.1 billion in 2024, then fell by 3.25% to $2.0 billion in 2025, then advanced by 3.7% to $2.1 billion in 2026.
• The last three Common Equity figures came in at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.

Peer Comparison